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Introduction
Major genetics factors for age-related macular degenera-
tion (AMD) have recently identified as susceptibility risk
factors, underlying the role of the vascular endothelial
growth factor (VEGF) system in AMD [1-4].
Aims
Our purpose was to determine whether (VEGF) gene
polymorphisms play a role in either susceptibility risk for
age-related macular degeneration (AMD) serum VEGF
levels (s-VEGF) variations and treatment with intravitreal
bevacizumab in Tunisians.
Methods
The case-control study included 157 patients with AMD
and 207 age-matched controls. In all patients, ophthal-
mological examinations, visual acuity, optical coherence
tomography (OCT), fundus photography and fluorescein
angiography were performed. Sixty-two patients were
treated with intravitreal bevacizumab. Single nucleotide
polymorphism (SNP) genotyping (+936 C>T, +405 C>G
and -2578 A>G) were performed using direct sequencing.
The serum VEGF was assayed by ELISA (R&D).
Results
The single SNP +936 TT and +405 CC genotypes were
significantly higher in AMD patients than in controls
(p=0.018 and p<10-3, respectively). Haplotype analysis of
SNP+936, +405 and -2578 revealed that TGA was asso-
ciated to exudative form of disease (p<0.0001). However,
single allele, genotype and haplotype association analyses
showed no significant association with s-VEGF levels var-
iations, clinical forms of AMD or better outcome for dis-
tance and reading visual acuity after three bevacizumab
injections.
Conclusions
Our results show that VEGF variants do contribute to the
susceptibility to AMD in Tunisian patients. Further
expression studies are needed to investigate the potential
pharmacologic role of these variants in antiangiogenesis
therapy.
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